NASD · Healthcare · Biotechnology · Netherlands
Pharming Group NV ADR is a small cap company (market value between $300 million and $2 billion) in the Biotechnology industry.
Intrinsic value, DCF valuation, financial health and value investing analysis for the Pharming Group NV ADR stock.
Overvalued: intrinsic value $8.24 per share, market price $12.23, margin of safety -48.5% (as of 2026-10-30).
Discounting its cash flows at 9.4% (average of 3 methods) values the shares at $8.24; the price of $12.23 is 48% above that value, and 76% of that value comes from beyond year five.
Leak Score: 42/100 on 11 of 12 signals (On Watch).
43 more in this industry show a wider margin of safety.
PHAR is overvalued (as of the 2026-10-30 close). Discounting its cash flows at 9.4% (average of 3 methods) values the shares at $8.24; the price of $12.23 is 48% above that value, and 76% of that value comes from beyond year five.
$8.24 per share (as of the 2026-10-30 close), against a market price of $12.23. That is a margin of safety of -48.5%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
42 out of 100, which we rate "On Watch", on 11 of 12 value investing signals.